The stock of United Therapeutics (NAS:UTHR, 30-year Financials) gives every indication of being significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $185.78 per share and the market cap of $8.3 billion, United Therapeutics stock shows every sign of being significantly overvalued. GF Value for United Therapeutics is shown in the chart below.
Because United Therapeutics is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth, which is estimated to grow 5.96% annually over the next three to five years.
Link: These companies may deliever higher future returns at reduced risk.
Investing in companies with poor financial strength has a higher risk of permanent loss of capital. Thus, it is important to carefully review the financial strength of a company before deciding whether to buy its stock. Looking at the cash-to-debt ratio and interest coverage is a great starting point for understanding the financial strength of a company. United Therapeutics has a cash-to-debt ratio of 2.16, which is worse than 74% of the companies in Biotechnology industry. GuruFocus ranks the overall financial strength of United Therapeutics at 7 out of 10, which indicates that the financial strength of United Therapeutics is fair. This is the debt and cash of United Therapeutics over the past years:
It is less risky to invest in profitable companies, especially those with consistent profitability over long term. A company with high profit margins is usually a safer investment than those with low profit margins. United Therapeutics has been profitable 9 over the past 10 years. Over the past twelve months, the company had a revenue of $1.5 billion and earnings of $9.05 a share. Its operating margin is 24.04%, which ranks better than 89% of the companies in Biotechnology industry. Overall, the profitability of United Therapeutics is ranked 7 out of 10, which indicates fair profitability. This is the revenue and net income of United Therapeutics over the past years:
One of the most important factors in the valuation of a company is growth. Long-term stock performance is closely correlated with growth according to GuruFocus research. Companies that grow faster create more value for shareholders, especially if that growth is profitable. The average annual revenue growth of United Therapeutics is -4.7%, which ranks in the middle range of the companies in Biotechnology industry. The 3-year average EBITDA growth is -4%, which ranks worse than 66% of the companies in Biotechnology industry.
Another way to evaluate a company’s profitability is to compare its return on invested capital (ROIC) to its weighted cost of capital (WACC). Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the ROIC is higher than the WACC, it indicates that the company is creating value for shareholders. Over the past 12 months, United Therapeutics’s ROIC was 11.41, while its WACC came in at 4.11. The historical ROIC vs WACC comparison of United Therapeutics is shown below:
In short, United Therapeutics (NAS:UTHR, 30-year Financials) stock shows every sign of being significantly overvalued. The company's financial condition is fair and its profitability is fair. Its growth ranks worse than 66% of the companies in Biotechnology industry. To learn more about United Therapeutics stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
